Reviewing Veracyte (NASDAQ:VCYT) & Competitive Technologies (OTCMKTS:CTTC)

Competitive Technologies (OTCMKTS:CTTC) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.

Valuation & Earnings

This table compares Competitive Technologies and Veracyte”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Competitive Technologies	N/A	N/A	N/A	N/A	N/A
Veracyte	$445.76 million	7.58	$24.14 million	$0.38	112.51

Veracyte has higher revenue and earnings than Competitive Technologies.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Competitive Technologies and Veracyte, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Competitive Technologies	0	0	0	0	0.00
Veracyte	1	2	5	1	2.67

Veracyte has a consensus price target of $46.14, suggesting a potential upside of 7.92%. Given Veracyte’s stronger consensus rating and higher probable upside, analysts clearly believe Veracyte is more favorable than Competitive Technologies.

Profitability

This table compares Competitive Technologies and Veracyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Competitive Technologies	N/A	N/A	N/A
Veracyte	6.12%	7.23%	6.58%

Summary

Veracyte beats Competitive Technologies on 8 of the 8 factors compared between the two stocks.

About Competitive Technologies

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.

About Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.